The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome； disruption of oncogenic miRNA function； cancer microenvironment remodeling； and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
